[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Adenosine.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Adenosine.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Adenosine.]
[L01BB02, mercaptopurine, The therapeutic efficacy of Adenosine can be decreased when used in combination with Mercaptopurine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Adenosine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Adenosine.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Adenosine.]
[A04AD10, dronabinol, The risk or severity of Tachycardia can be increased when Dronabinol is combined with Adenosine.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Adenosine.]
[R03DA07, theobromine, The therapeutic efficacy of Adenosine can be decreased when used in combination with Theobromine.]
[R03DA04, theophylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Theophylline.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Adenosine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Adenosine.]
[C01BB04, aprindine, Adenosine may increase the arrhythmogenic activities of Aprindine.]
[S01ED01, timolol, Timolol may increase the arrhythmogenic activities of Adenosine.]
[N02AX02, tramadol, The risk or severity of Tachycardia can be increased when Tramadol is combined with Adenosine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Adenosine.]
[A03AB12, mepenzolate, The risk or severity of Tachycardia can be increased when Adenosine is combined with Mepenzolate.]
[N05AA05, triflupromazine, The risk or severity of Tachycardia can be increased when Triflupromazine is combined with Adenosine.]
[N04AA01, trihexyphenidyl, The risk or severity of Tachycardia can be increased when Trihexyphenidyl is combined with Adenosine.]
[A03AA05, trimebutine, Adenosine may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Adenosine may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Adenosine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Adenosine.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Adenosine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Adenosine.]
[A03BB01, butylscopolamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Butylscopolamine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Vandetanib.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Adenosine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Adenosine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Adenosine.]
[C08DA01, verapamil, Adenosine may increase the arrhythmogenic activities of Verapamil.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Adenosine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ziprasidone.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Adenosine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Adenosine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Adenosine.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Adenosine.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Adenosine.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Octopamine.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Adenosine.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Adenosine.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Adenosine.]
[R06AC06, thonzylamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Thonzylamine.]
[G04BD10, darifenacin, The risk or severity of Tachycardia can be increased when Darifenacin is combined with Adenosine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Adenosine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Bedaquiline.]
[C04AX11, bencyclane, Adenosine may increase the arrhythmogenic activities of Bencyclane.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Adenosine.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Adenosine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Adenosine.]
[N06AX28, levomilnacipran, The risk or severity of Tachycardia can be increased when Adenosine is combined with Levomilnacipran.]
[C08EA02, bepridil, Adenosine may increase the arrhythmogenic activities of Bepridil.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Adenosine is combined with Droxidopa.]
[C07AB04, acebutolol, Adenosine may increase the arrhythmogenic activities of Acebutolol.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Adenosine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Adenosine.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Adenosine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Adenosine.]
[D11AA01, glycopyrronium, The risk or severity of Tachycardia can be increased when Adenosine is combined with Glycopyrronium.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Eliglustat.]
[N04AA02, biperiden, The risk or severity of Tachycardia can be increased when Adenosine is combined with Biperiden.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Adenosine.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Panobinostat.]
[A03AA09, difemerine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Difemerine.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Adenosine.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Adenosine.]
[N04BC01, bromocriptine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Bromocriptine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Adenosine.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Adenosine.]
[C07AA19, bupranolol, Adenosine may increase the arrhythmogenic activities of Bupranolol.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Adenosine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Adenosine.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Adenosine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ribociclib.]
[R03CC12, bambuterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Bambuterol.]
[R03DA08, bamifylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Bamifylline.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Adenosine.]
[N06BC01, caffeine, The therapeutic efficacy of Adenosine can be decreased when used in combination with Caffeine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Adenosine.]
[P03AC02, bioallethrin, Adenosine may increase the arrhythmogenic activities of Bioallethrin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Adenosine.]
[C07AB07, bisoprolol, The therapeutic efficacy of Adenosine can be increased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Bitolterol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Adenosine.]
[N04AA11, bornaprine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Bornaprine.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Acetyldigoxin is combined with Adenosine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Adenosine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Macimorelin.]
[N03AF01, carbamazepine, Carbamazepine may increase the atrioventricular blocking (AV block) activities of Adenosine.]
[A03AA03, camylofine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Carbinoxamine.]
[C07AG02, carvedilol, Adenosine may increase the arrhythmogenic activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Cannabidiol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Encorafenib.]
[C07AB08, celiprolol, Adenosine may increase the arrhythmogenic activities of Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ivosidenib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Adenosine.]
[R06AA06, chlorphenoxamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Chlorphenoxamine.]
[R03DA02, oxtriphylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Oxtriphylline.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Adenosine.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Amifampridine.]
[C01BG07, cifenline, Adenosine may increase the arrhythmogenic activities of Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Adenosine.]
[S01ED05, carteolol, Adenosine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Adenosine.]
[N06AX27, esketamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Esketamine.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Adenosine.]
[C03BX03, cicletanine, Adenosine may increase the arrhythmogenic activities of Cicletanine.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Entrectinib.]
[N07XX11, pitolisant, Adenosine may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Adenosine.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Adenosine.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Adenosine.]
[C08CA16, clevidipine, Adenosine may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Adenosine may increase the arrhythmogenic activities of Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Adenosine.]
[A03AA08, dihexyverine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dopexamine.]
[G04BD09, trospium, The risk or severity of Tachycardia can be increased when Trospium is combined with Adenosine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Adenosine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Adenosine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Adenosine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Adenosine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Adenosine.]
[N06BX18, vinpocetine, Adenosine may increase the arrhythmogenic activities of Vinpocetine.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Berotralstat.]
[M09AA01, hydroquinine, Adenosine may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Adenosine.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Adenosine.]
[N06BA10, fenethylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Fenethylline.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Adenosine is combined with Fenozolone.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Adenosine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Adenosine.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Adenosine.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Adenosine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Adenosine.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Adenosine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Clemastine.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Clenbuterol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Adenosine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Adenosine.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Clomipramine.]
[S01EA04, clonidine, The risk or severity of Tachycardia can be increased when Clonidine is combined with Adenosine.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Adenosine.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Cocaine.]
[A03AB10, hexocyclium, The risk or severity of Tachycardia can be increased when Adenosine is combined with Hexocyclium.]
[A03BB06, homatropine methylbromide, The risk or severity of Tachycardia can be increased when Adenosine is combined with Homatropine methylbromide.]
[C01BA13, hydroquinidine, Adenosine may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Adenosine.]
[A04AA03, tropisetron, Adenosine may increase the arrhythmogenic activities of Tropisetron.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Desloratadine.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Adenosine is combined with Isometheptene.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Adenosine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Emedastine.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Adenosine.]
[C08CA09, lacidipine, Adenosine may increase the arrhythmogenic activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Adenosine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Adenosine.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Lomefloxacin.]
[C08CA11, manidipine, Adenosine may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Adenosine is combined with Mefenorex.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Adenosine.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Adenosine.]
[N04AA03, methixene, The risk or severity of Tachycardia can be increased when Metixene is combined with Adenosine.]
[C04AX01, cyclandelate, Adenosine may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Adenosine.]
[N05AD03, metylperon, Adenosine may increase the arrhythmogenic activities of Melperone.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Adenosine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Adenosine.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Adenosine.]
[A04AD11, nabilone, The risk or severity of Tachycardia can be increased when Nabilone is combined with Adenosine.]
[C07AB12, nebivolol, Adenosine may increase the arrhythmogenic activities of Nebivolol.]
[C01DX16, nicorandil, Adenosine may increase the arrhythmogenic activities of Nicorandil.]
[C01CA23, theodrenaline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Norfenefrine.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Adenosine.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Adenosine.]
[C01AA07, deslanoside, Adenosine may increase the arrhythmogenic activities of Deslanoside.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Adenosine.]
[N04AA08, dexetimide, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dexetimide.]
[G04BD04, oxybutynin, The risk or severity of Tachycardia can be increased when Adenosine is combined with Oxybutynin.]
[A03AA01, oxyphencyclimine, The risk or severity of Tachycardia can be increased when Oxyphencyclimine is combined with Adenosine.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Adenosine.]
[N06AB05, paroxetine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Paroxetine.]
[C04AD01, pentifylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Pentifylline.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Adenosine.]
[A03AA07, dicyclomine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dicyclomine.]
[A03AX04, pinaverium, Adenosine may increase the arrhythmogenic activities of Pinaverium.]
[A03AB14, pipenzolate, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Erlotinib.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of Tachycardia can be increased when Adenosine is combined with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Adenosine.]
[A03AB11, poldine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Poldine.]
[C01AA04, digitoxin, Adenosine may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Adenosine.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Adenosine.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Adenosine.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dimenhydrinate.]
[R06AB03, dimethindene, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Procaterol.]
[N06BC02, propentofylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Propentofylline.]
[R03DA03, proxyphylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Proxyphylline.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Adenosine.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Adenosine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Cisapride.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Reproterol.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Adenosine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Adenosine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Adenosine.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Adenosine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Adenosine.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Adenosine.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Adenosine.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Adenosine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Adenosine.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dobutamine.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Domperidone.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Adenosine.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Adenosine.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Adenosine.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Adenosine.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Adenosine.]
[A08AA10, sibutramine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Sibutramine.]
[R03DA01, dyphylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Dyphylline.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Sultopride.]
[C07AB13, talinolol, Adenosine may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Temafloxacin.]
[G04BD05, terodiline, Adenosine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Adenosine may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Tetryzoline.]
[G04BD01, emepronium, The risk or severity of Tachycardia can be increased when Adenosine is combined with Emepronium.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Adenosine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Toremifene.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Tramazoline.]
[A03AB08, tridihexethyl, The risk or severity of Tachycardia can be increased when Tridihexethyl is combined with Adenosine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Adenosine.]
[N04AA12, tropatepine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Tulobuterol.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Adenosine.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Adenosine.]
[N06AX16, venlafaxine, The risk or severity of Tachycardia can be increased when Venlafaxine is combined with Adenosine.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Xamoterol.]
[S01GA03, xylometazoline, Adenosine may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Adenosine may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Epinephrine.]
[N03AX15, zonisamide, Adenosine may increase the arrhythmogenic activities of Zonisamide.]
[C02AC02, guanfacine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Guanfacine.]
[C01BG01, moricizine, Adenosine may increase the arrhythmogenic activities of Moricizine.]
[G02AB03, ergonovine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Ergometrine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Adenosine.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Gepefrine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Adenosine.]
[N04AA05, profenamine, The risk or severity of Tachycardia can be increased when Profenamine is combined with Adenosine.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Adenosine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of Tachycardia can be increased when Etomidate is combined with Adenosine.]
[C01BA05, ajmaline, Adenosine may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Adenosine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Adenosine.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Terfenadine.]
[C01BB03, tocainide, Adenosine may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Adenosine may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Adenosine.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Adenosine.]
[C08CA02, felodipine, Adenosine may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Adenosine may increase the arrhythmogenic activities of Fendiline.]
[R03CC04, fenoterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Fenoterol.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Adenosine.]
[G04BD02, flavoxate, The risk or severity of Tachycardia can be increased when Adenosine is combined with Flavoxate.]
[C01BC04, flecainide, Adenosine may increase the arrhythmogenic activities of Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Adenosine.]
[N07CA03, flunarizine, Adenosine may increase the arrhythmogenic activities of Flunarizine.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Adenosine.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Adenosine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Flupentixol.]
[N05AG01, fluspirilene, Adenosine may increase the arrhythmogenic activities of Fluspirilene.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Adenosine is combined with Adrafinil.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Adenosine.]
[C08DA02, gallopamil, Adenosine may increase the arrhythmogenic activities of Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Adenosine.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Adenosine.]
[C01CA21, cafedrine, The therapeutic efficacy of Adenosine can be decreased when used in combination with Cafedrine.]
[N03AD03, methsuximide, Adenosine may increase the arrhythmogenic activities of Methsuximide.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Adenosine.]
[N05CM18, dexmedetomidine, The risk or severity of Tachycardia can be increased when Dexmedetomidine is combined with Adenosine.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Adenosine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Adenosine.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Adenosine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Adenosine.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Adenosine.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Quetiapine.]
[C09CA01, losartan, Adenosine may increase the arrhythmogenic activities of Losartan.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Adenosine may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Adenosine may increase the arrhythmogenic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Adenosine.]
[G04BD06, propiverine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Adenosine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Rilmenidine.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Adenosine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Adenosine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Adenosine.]
[N06AX17, milnacipran, The risk or severity of Tachycardia can be increased when Adenosine is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of Tachycardia can be increased when Adenosine is combined with Piperidolate.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Adenosine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Anagrelide.]
[C07AA01, alprenolol, Adenosine may increase the arrhythmogenic activities of Alprenolol.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Adenosine.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Adenosine.]
[R03CB01, isoproterenol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Isoxsuprine.]
[N01AX03, ketamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Ketamine.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Adenosine.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Adenosine.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mizolastine.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Arbutamine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Nalidixic acid.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Labetalol is combined with Adenosine.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Adenosine.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Adenosine.]
[C08EX01, lidoflazine, Adenosine may increase the arrhythmogenic activities of Lidoflazine.]
[A07DA03, loperamide, Adenosine may increase the arrhythmogenic activities of Loperamide.]
[V04CC02, magnesium sulfate, Adenosine may increase the arrhythmogenic activities of Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Adenosine.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Metildigoxin is combined with Adenosine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Adenosine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Mephentermine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Adenosine.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Adenosine.]
[N06BA03, methamphetamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Metamfetamine.]
[A03AB07, methantheline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Methantheline.]
[N02BG08, ziconotide, Adenosine may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Adenosine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Methoxamine.]
[R03DA05, aminophylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Adenosine.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Adenosine.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Adenosine.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Adenosine.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Adenosine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Mifepristone.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Adenosine.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Adenosine.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Pazopanib.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Adenosine.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Adenosine.]
[C07AA12, nadolol, Adenosine may increase the arrhythmogenic activities of Nadolol.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Adenosine.]
[N06AX21, duloxetine, The risk or severity of Tachycardia can be increased when Duloxetine is combined with Adenosine.]
[N01AH06, remifentanil, The risk or severity of Tachycardia can be increased when Adenosine is combined with Remifentanil.]
[C01CX08, levosimendan, Adenosine may increase the arrhythmogenic activities of Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Desvenlafaxine.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Adenosine.]
[N07BA01, nicotine, Nicotine may increase the atrioventricular blocking (AV block) and tachycardic activities of Adenosine.]
[C08CA05, nifedipine, Adenosine may increase the arrhythmogenic activities of Nifedipine.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Adenosine.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Adenosine.]
[C08CA08, nitrendipine, Adenosine may increase the arrhythmogenic activities of Nitrendipine.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Adenosine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Adenosine.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Adenosine.]
[G02CA02, nylidrin, Adenosine may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Adenosine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Ofloxacin.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Orciprenaline.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Adenosine.]
[C07AA02, oxprenolol, Adenosine may increase the arrhythmogenic activities of Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Oxymetazoline.]
[A03AB03, oxyphenonium, The risk or severity of Tachycardia can be increased when Oxyphenonium is combined with Adenosine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Adenosine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Asenapine.]
[M03AC01, pancuronium, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Papaverine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Adenosine.]
[G04BD11, fesoterodine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Fesoterodine.]
[N05AG03, penfluridol, Adenosine may increase the arrhythmogenic activities of Penfluridol.]
[C04AD03, pentoxifylline, The therapeutic efficacy of Adenosine can be decreased when used in combination with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pergolide.]
[C08EX02, perhexiline, Adenosine may increase the arrhythmogenic activities of Perhexiline.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Adenosine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Adenosine.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Adenosine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Adenosine.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Levofloxacin.]
[C08CX01, mibefradil, Adenosine may increase the arrhythmogenic activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Pimozide.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Saquinavir.]
[A02BX03, pirenzepine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pirenzepine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pizotifen.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Adenosine.]
[C07AB01, practolol, Adenosine may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Adenosine may increase the arrhythmogenic activities of Prajmaline.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Antazoline.]
[C01DX02, prenylamine, Adenosine may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Primaquine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Probucol.]
[C01BA02, procainamide, Adenosine may increase the arrhythmogenic activities of Procainamide.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Adenosine.]
[N04AA04, procyclidine, The risk or severity of Tachycardia can be increased when Procyclidine is combined with Adenosine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Adenosine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Adenosine.]
[C01BC03, propafenone, Adenosine may increase the arrhythmogenic activities of Propafenone.]
[A03AB05, propantheline, The risk or severity of Tachycardia can be increased when Adenosine is combined with Propantheline.]
[N05CM06, propiomazine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Adenosine.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Adenosine.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Adenosine.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Adenosine.]
[A03AB15, diphemanil, The risk or severity of Tachycardia can be increased when Adenosine is combined with Diphemanil.]
[A03AB09, isopropamide, The risk or severity of Tachycardia can be increased when Adenosine is combined with Isopropamide.]
[S01FA03, methscopolamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Methscopolamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Adenosine.]
[C01BA01, quinidine, Adenosine may increase the arrhythmogenic activities of Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Quinine.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Adenosine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Ritodrine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Roxithromycin.]
[S01FA02, scopolamine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Scopolamine.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Adenosine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Valproic acid.]
[C01DA14, isosorbide mononitrate, Adenosine may increase the vasodilatory activities of Isosorbide mononitrate.]
[R03BB01, ipratropium bromide, The risk or severity of Tachycardia can be increased when Ipratropium is combined with Adenosine.]
